The "Paroxysmal Supraventricular Tachycardia Market"is anticipated to increase from USD xxx billion in 2023 to USD xxx billion by 2031, with a strong compound annual growth rate (CAGR) of xxx% from ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

All the complement inhibitor therapies for PNH could face a tough time competing with new oral therapies that are also reaching or approaching potential market launch. That includes Novartis ...

The question is whether the added convenience offered by crovalimab will be enough to carve out a niche for the drug in the increasingly crowded PNH market. AZ is working hard to build a market ...

for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth. “SYFOVRE is the market-leading treatment for GA, with more than 120% net sales ...

A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...